OCGN
Ocugen, Inc.

Ocugen, Inc.OCGN

Healthcare · Biotechnology
0.76USD
+7.34%
Oct 28, 2026
OCGN overview ready
Developer of gene therapies for inherited retinal diseases
Clinical-stage ophthalmic genetic-medicines developer focused on modifier gene therapies for retinal disease; its value is predominantly tied to clinical, regulatory, manufacturing, and financing progress rather than current product sales.
Narrative is still early
Exposed to the Genetic Medicines for Rare and Degenerative Diseases narrative through Ophthalmic Gene Therapies for Retinal Degeneration — pure play.
Price trend is broken
Longer-term context reads damaged structure, with a near-term setup of distribution pressure.
The tactical setup reads distribution pressure, but the weekly structure is broken.
Fair valuation
The price broadly reflects the strength of its balance sheet, with upside and risk reasonably balanced.
Fundamentals under pressure
Ev / sales is weak.
Primary risk
Clinical trial failure or delays.
Market Oct 27Filing Jun 30Price action Sep 17Research Sep 17

Conviction Level

CompanyFit6.0PriceAction3.4Valuation3.5CompanyPosition9.3BusinessQuality—

Conviction uses Company Fit, Price Action, Valuation, Business Quality. Company Position is research context, not an input.

Theme leadershipGroup context · not a Conviction input
Gene TherapyLagging
vs SPY
−16.6pp
Theme return
−16.1%
Beating SPY
0 of 8
21 sessions to Oct 27, 2026 · ranked 54 of 59 themes
Price
Loading price history…

Price Action

Price trend is broken
Longer-term context reads damaged structure, with a near-term setup of distribution pressure.
The tactical setup reads distribution pressure, but the weekly structure is broken.
EntryWeak / unconfirmed recovery

The daily chart may be improving, but the weekly fast averages have not been reclaimed — the recovery is not yet confirmed on the higher timeframe.

Key Financials

Market Cap
$257.7M
Avg Volume (60D)
7.7M
60 sessions
Revenue Growth YoY
+8.8%
FY2025 vs FY2024
Gross Margin
-855.3%
Free Cash Flow Yield
-23.7%
P/E
N/M
EV / Sales
34.8x
Market metrics as of Oct 27, 2026
Financial results for the period ended Jun 30, 2026
Filed balance-sheet data as of Jun 30, 2026

Fundamentals & Valuation

The available comparisons disagreed; the intrinsic comparison is the more reliable method for this business and the others are published as dissent.
This company has a Fair valuation stance because the price broadly reflects the strength of its balance sheet, with upside and risk reasonably balanced.

Company Research

Thesis
Clinical-stage ophthalmic genetic-medicines developer focused on modifier gene therapies for retinal disease; its value is predominantly tied to clinical, regulatory, manufacturing, and financing progress rather than current product sales.
Opportunity
Moderate opportunity
Development and eventual adoption of durable genetic medicines intended to preserve or restore vision in inherited and degenerative retinal diseases, where unmet need and chronic-treatment burden support one-time or long-duration interventions.
Key risk
Clinical trial failure or delays.

Economic classification

Loading the economic classification…

Business & Markets

Healthcare · Biotechnology
What they do

Ocugen, Inc. discovers, develops, and commercializes novel gene and cell therapies, biologics, and vaccines aimed at improving patient health, focusing on inherited retinal diseases and other conditions.

How it earns

The company generates revenue primarily through the commercialization and licensing of its biopharmaceutical products and therapies.

Products & services
OCU400 gene therapy for inherited retinal diseases
OCU410 gene therapy for dry age-related macular degeneration
Customers & end markets
Patients with inherited retinal diseases
Healthcare providers and medical institutions
Market position

Niche player specializing in gene therapies for rare ophthalmic conditions.

Demand drivers
Low cyclicality

Healthcare demand for gene therapies is relatively inelastic and driven by medical need rather than economic cycles.